Q1 2026 IVD Market Insights

1 . China's volume-based pricing policy simultaneously crushed pricing and volume for every major Core Lab and Molecular player with meaningful Chinese market exposure; Roche, Siemens, and Danaher all reported headline declines that masked fundamentally healthy performance outside China.

2. The respiratory hangover hit Molecular Dx hardest, with BIOFIRE down 23% and Cepheid respiratory revenue down approximately 25%. Both declines trace to a single mild season, not any structural shift in platform competitiveness.

3. And in Micro / Specialty, Waters accelerated the BACTEC FXI blood culture launch 3 to 5 months ahead of plan, Roche Pathology delivered 12% growth, and after the quarter closed, Thermo Fisher announced the divestiture of its microbiology business unit. The competitive conversations that weren’t happening six months ago are happening now.

Q1 2026 IVD Performance Scorecard

0–100 benchmark across four pillars: Revenue Performance, Innovation, M&A Activity, and Market Sentiment. Scores reflect IVD business units only.

Score 90–100: Best-in-class · 70–89: Solid performance · 55–69: Mixed conditions · 40–54: Structural challenges · Below 40: Distress.

All figures in USD.

Core Lab: A Market Splitting Between the Dominant and the Distressed

Core Lab this quarter is two stories running simultaneously: structural dominance being reinforced on one side, structural crisis accelerating on the other.

Siemens Diagnostics: From Difficulty to Crisis

Siemens Healthineers reported approximately $1.1B in Diagnostics revenue, down 6.5% compared to the same period last year.

Management formally initiated a carve-out of the Diagnostics division, moving the conversation from a future option to a concrete restructuring timeline. For lab directors with expiring Atellica contracts, it raises real questions about platform investment, roadmap continuity, and long-term support. For competitors, it is the most significant Core Lab displacement opportunity in a decade.



“We are also taking measures for the future of the company by initiating the next steps to create options for Diagnostics...”

— Siemens Management

Abbott: Defining the New Standard for Core Lab Dominance

Abbott's Core Lab performance moved in the opposite direction entirely. Core Lab Diagnostics grew 3% compared to the prior year, with growth across the U.S., Europe, and Latin America. What stands out most: a contract renewal rate exceeding 90% and a greater-than-55% win rate in contested evaluations. One out of every two contested evaluations goes to Abbott.

This is not chemistry performance. This is the commercial compound interest of the Alinity connectivity ecosystem. Separately, Abbott’s March 2026 acquisition of Exact Sciences adds a high-growth cancer diagnostics and screening business to the portfolio, though that revenue runs outside Core Lab. The combination of platform stickiness and renewal metrics is producing a competitive position that is increasingly difficult to challenge directly.



“We are renewing contracts at a very high renewal rate, call it 90% plus... Our win rates are 55% plus; in new business, we are able to win one out of two.”

— Abbott Management

QuidelOrtho: #1 NPS With Room to Grow

QuidelOrtho’s Labs Division, which represents approximately 55% of total company revenue, delivered +7% growth in Q1, driven by clinical chemistry strength and consistent execution in the mid-volume hospital segment. The division holds a 96% recurring revenue base and the #1 Net Promoter Score in Core Lab, a commercial asset that directly reduces churn at renewal and is genuinely rare at this scale.

The mid-volume hospital market remains under-penetrated, providing a durable growth runway that does not depend on displacing entrenched competitors at major academic centers.

Roche: China Drag Masking Ex-China Strength

Roche’s Core Lab reported approximately $2.0B, down 6% reported, but the China revenue impact is distorting the overall picture. Excluding China, Core Lab grew 8% outside China, a fundamentally healthy business temporarily obscured by China pricing policy. China revenue declined 14% as pricing and volume were simultaneously compressed. Management expects China comps to begin lapping in Q3/Q4 2026, at which point the underlying strength should become visible in reported numbers.

Danaher / Beckman Coulter: Gaining Share Quietly

Danaher reported Core Lab revenue down 4%, but Beckman Coulter grew at low-to-mid single digit rates outside China, confirming active global share capture obscured by the China revenue decline. The DxI 9000 high-throughput immunoassay analyzer continues to win competitive evaluations, and the FDA clearance of HBc IgM expands the platform’s menu into acute hepatitis B serology, strengthening the case for winning accounts away from incumbent platforms.



Molecular Dx: Respiratory Hangover, New Entrants, and a Policy-

Driven Collapse

Q1 2026 was a difficult quarter to read in Molecular Diagnostics. BIOFIRE down 23%, Cepheid respiratory down approximately 25%, DiaSorin molecular down 20%. The numbers look alarming until you recognize that all three trace to a single cause: a lighter-than-normal Northern Hemisphere respiratory season. This is seasonality, not share loss.



The more important signal was what happened beneath the respiratory line. Cepheid’s non-respiratory menu grew at mid-teens rates, with sexual health and hospital-acquired infection assays up 20%. The case for menu diversification is being validated in real time. Platforms that invested in expanding beyond flu and COVID panels during 2022–2024 are now generating durable consumable revenue regardless of season severity. Platforms that didn’t are fully exposed.

BIOFIRE and the Respiratory Concentration Problem

bioMérieux bore the sharpest respiratory impact of any molecular player. Molecular sales declined 19% to approximately $476M, with BIOFIRE respiratory panels down 23%. This triggered a full-year guidance downward revision and an 18% decline in instrument orders in a soft market for new placements.

The SPOTFIRE near-patient platform is the strategic offset, with installs exceeding 6,800 globally and new EU IVDR CE clearances. The near-patient pivot is the right long-term direction, but it doesn’t cushion a respiratory-heavy Q1 in the short term.



“Acknowledging the particularly soft market environment that weighed on first-quarter performance, bioMérieux has revised its full-year guidance downward.”

— bioMérieux Management

QuidelOrtho and LEX: Near-Patient Molecular Gets a Well-Funded New Entrant

The most strategically significant Molecular Dx development happened after quarter close: QuidelOrtho’s $100M acquisition of LEX Diagnostics closed April 20. LEX brings FDA-cleared near-patient PCR with results in under 10 minutes, filling the gap between rapid antigen tests and traditional lab-based PCR.

The distribution advantage is the differentiator. QuidelOrtho’s 96% recurring hospital base and #1 NPS give LEX instant access to hospital accounts that previously required a separate near-patient molecular vendor relationship. GeneXpert and SPOTFIRE now face a well-funded competitor with an unprecedented commercial infrastructure advantage in the near-patient PCR segment.

Qiagen and the Immigration Policy Headwind

QuantiFERON TB revenue fell 5% on $113M, a $30–35M headwind driven by declining U.S. immigration visa issuance and Middle East conflict disruption. Management slashed full-year guidance from at least +5% to 1 to 2%, characterizing the decline as a demand rebasing rather than structural erosion of the long-term TB testing opportunity.



“QuantiFERON was affected by the significant decline in immigration testing demand... we view this as a rebasing of demand, not a change in the overall long-term opportunity for latent TB testing.”

— Qiagen Management

QIAstat-Dx ($36M, down 1%) and the April 14 launch of the QIAstat-Dx BCID AMR panel for syndromic bloodstream infection represent Qiagen’s long-term growth pivot away from QuantiFERON. Critical care syndromic commands premium reimbursement and is structurally insulated from immigration policy volatility.

Microbiology / Specialty Dx: The Quarter That Reshaped the Segment

Microbiology / Specialty Dx saw more consequential competitive movement in Q1 2026, and in the weeks immediately following, than in any recent comparable period. Three major developments landed in rapid succession, each with implications that will persist well into 2027.

Waters / BD: The Most Aggressive Commercial Push in Microbiology in Years

Waters' Advanced Diagnostics Division generated $349M in its first full quarter as a standalone business unit, with Microbiology growing 10%. Waters accelerated the BACTEC FXI blood culture system launch by 3 to 5 months versus the inherited BD business plan. Of the 12,000 aging BACTEC instruments identified for replacement, more than half are over 5 years old and more than a quarter are over 10 years old. Waters simultaneously identified approximately 700 U.S. reagent rental contracts currently out of compliance, representing a double-digit million dollar annual revenue shortfall they are actively moving to recover.

12,000 aging BACTEC instruments sit in hospital microbiology labs globally. Waters is executing simultaneously on proactive replacement sales targeting those accounts and reactive compliance enforcement creating financial pressure on lapsed accounts. The combination of both strategies in a single quarter creates an exceptional revenue setup for Q2–Q4 2026 that competitors in blood culture, primarily bioMérieux BACT/ALERT, need to take seriously.



“Acknowledging the particularly soft market environment that weighed on first-quarter performance, bioMérieux has revised its full-year guidance downward.”

— bioMérieux Management

Thermo Fisher Microbiology: A Divestiture and Its Implications

Thermo Fisher signed a binding $1.075B agreement to divest its Microbiology business (Sensititre and Trek, approximately $645M in annual revenue) to Astorg PE on April 27. The deal has not yet closed (expected H2 2026), but labs on these platforms face a fundamental question: is a PE-owned microbiology vendor with uncertain long-term R&D commitment the right strategic partner for the next 5–7 years?

For competitors, including Waters/BD BACTEC FXI, bioMérieux VITEK/BACT/ALERT, and Bruker MALDI Biotyper, the Thermo Fisher installed base represents a live re-evaluation moment that is open now and will remain open through the close timeline.

Bio-Rad: QC Fortress Stable, Clinical Dx Resilient

Bio-Rad’s Clinical Diagnostics segment posted $364M, up 1.9% compared to the same period last year. An $11M Middle East logistics disruption in EMEA reduced what would otherwise have been a stronger result. The quality control franchise remains non-discretionary. Accreditation requirements tie labs to specific QC programs through survey participation, creating near-permanent switching barriers. The IH-500 blood typing platform and BioPlex 2200 autoimmune platform provide durable specialty Dx revenue alongside QC.

What Changed After the Quarter Closed

Q1 closed March 31, but the weeks that followed delivered a series of strategic moves that materially alter the competitive picture heading into Q2. These are not routine announcements; each one changes account-level commercial dynamics in ways that IVD marketing and commercial teams need to act on now.

What to Watch in Q2 2026

Several dynamics will determine whether Q1’s underlying resilience translates into visible performance improvement in Q2, or whether macro headwinds continue to distort the picture.

China pricing policy lapping. Roche and Danaher management both indicated that China comps should begin normalizing in Q3/Q4. If China pricing pressures ease sooner than expected in Q2, the underlying Core Lab performance could become visible earlier. Watch China segment commentary closely in Q2 results.

Respiratory season normalization. Q2 is not a high-volume respiratory quarter regardless of season severity, so the BIOFIRE and Cepheid respiratory recovery will not be visible until Q3/Q4. The real Q2 signal for Molecular Dx is non-respiratory menu growth. The platforms that continue to grow sexual health, HAI, and critical care panels in the respiratory off-season are the ones with structural resilience.

Siemens carve-out timeline. Management has initiated the carve-out process, but the timeline to completion is unclear. Every quarter of uncertainty is a quarter in which lab directors with expiring Atellica contracts are more open to competitive conversations. Watch for any formal announcements on carve-out structure or timeline in Q2.

LEX commercial ramp. The LEX acquisition closed April 20. Q2 will be the first quarter in which QuidelOrtho is actively selling LEX into its hospital network. Menu expansion, TAT at scale, and instrument placement velocity will determine whether the distribution advantage translates into rapid share gains or a slower build.



Thermo Fisher micro transition. The Astorg PE divestiture is expected to close H2 2026. As the close date comes into clearer view, labs on Sensititre and Trek will face increasing urgency around their platform decisions. Q2 is the window for competitors to engage these accounts before transition-related inertia sets in.

About the Author

James Garvin, IVD Practice Leader & Sr. Consultant, partners with the world’s leading IVD manufacturers to translate Voice of Customer and market intelligence into winning commercial strategies across product development, pricing, and positioning. James previously held commercial and marketing strategy roles at Beckman Coulter and Thermo Fisher Scientific.

     ✉︎ Jgarvin@EnsolveResearch.com



Work with Ensolve Research

Ensolve Research is a MedTech marketing research consultancy specializing in the IVD and medical technology industries. We design and execute primary research that translates market signals into actionable marketing & commercial intelligence.

Our 2026 IVD research capabilities include:

• Global VOC Studies — Structured interviews and surveys with lab directors, clinical scientists, and procurement leaders across US, EMEA, and APAC
• Pricing Research — Conjoint analysis, willingness-to-pay, and price elasticity studies for novel assay and platform launches
• Platform Displacement Research — Identifying the specific triggers that cause lab directors to switch platforms
• Sample Journey & Workflow Mapping — Ethnographic research into clinical diagnostic workflows to identify unmet needs
• Concept & Messaging Optimization — Pre-launch testing of clinical claims and value propositions with target buyer segments
• Competitive Wargaming — Structured research-based competitive positioning studies for platform launch strategy

If your team is evaluating a platform launch, menu expansion, or competitive displacement strategy in 2026, these questions are not theoretical — they are commercial decisions.

Ensolve Research designs VOC research to answer them before launch.